Total Payments
$106,589
2024 Payments
$1,388
Companies
25
Transactions
122
Medicare Patients
2,031
Medicare Billing
$280,077
Payment Breakdown by Category
Consulting$68,768 (64.5%)
Research$17,241 (16.2%)
Travel$13,362 (12.5%)
Food & Beverage$3,684 (3.5%)
Other$3,531 (3.3%)
Education$2.32 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $68,768 | 20 | 64.5% |
| Unspecified | $17,241 | 4 | 16.2% |
| Travel and Lodging | $13,362 | 33 | 12.5% |
| Food and Beverage | $3,684 | 61 | 3.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,531 | 3 | 3.3% |
| Education | $2.32 | 1 | 0.0% |
Payments by Type
General
$89,347
118 transactions
Research
$17,241
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $23,496 | 10 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $16,878 | 28 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $16,013 | 30 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $11,045 | 5 | $0 (2023) |
| Astellas Pharma US Inc | $6,211 | 2 | $0 (2017) |
| Halozyme Inc | $4,421 | 10 | $0 (2018) |
| Genentech, Inc. | $3,983 | 4 | $0 (2017) |
| Gilead Sciences, Inc. | $3,644 | 2 | $0 (2023) |
| Eli Lilly and Company | $3,597 | 7 | $0 (2019) |
| Roche Diagnostics International Ltd | $3,331 | 4 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,388 | 5 | Ipsen Innovation ($870.00) |
| 2023 | $7,853 | 14 | E.R. Squibb & Sons, L.L.C. ($5,433) |
| 2022 | $4,600 | 3 | Deciphera Pharmaceuticals Inc. ($2,580) |
| 2021 | $6,190 | 3 | Gilead Sciences, Inc. ($3,610) |
| 2020 | $10,250 | 2 | AstraZeneca Pharmaceuticals LP ($10,250) |
| 2019 | $31,137 | 28 | Amgen Inc. ($15,543) |
| 2018 | $22,221 | 32 | Merck Sharp & Dohme Corporation ($6,978) |
| 2017 | $22,950 | 35 | Amgen Inc. ($7,451) |
All Payment Transactions
122 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | Ipsen Innovation | Somatuline Depot (Drug) | Consulting Fee | Cash or cash equivalent | $870.00 | General |
| Category: Oncology/Endocrinology | ||||||
| 09/05/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $2.88 | General |
| Category: ONCOLOGY | ||||||
| 01/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $257.68 | General |
| 01/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $178.62 | General |
| 01/02/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $79.06 | General |
| 12/18/2023 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $4,050.00 | General |
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $677.34 | General |
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $355.00 | General |
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $179.67 | General |
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $60.98 | General |
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $50.01 | General |
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 11/09/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| 08/16/2023 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Consulting Fee | Cash or cash equivalent | $1,980.00 | General |
| Category: Oncology | ||||||
| 08/16/2023 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Travel and Lodging | Cash or cash equivalent | $58.00 | General |
| Category: Oncology | ||||||
| 06/04/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $78.76 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $34.18 | General |
| 06/01/2023 | TAIHO ONCOLOGY, INC. | LONSURF (Drug) | Food and Beverage | In-kind items and services | $134.00 | General |
| Category: Oncology | ||||||
| 01/19/2023 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $134.70 | General |
| Category: Oncology | ||||||
| 11/01/2022 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $1,518.75 | General |
| 07/06/2022 | Deciphera Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $2,580.00 | General |
| 03/07/2022 | Amgen Inc. | IMLYGIC (Biological) | Travel and Lodging | Cash or cash equivalent | $501.54 | General |
| Category: Oncology | ||||||
| 07/22/2021 | Exelixis Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,980.00 | General |
| 03/31/2021 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,610.00 | General |
| 02/18/2021 | Corcept Therapeutics | Korlym (Drug) | Consulting Fee | Cash or cash equivalent | $600.00 | General |
| Category: Endocrinology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Talimogene Laherparepvec: Review of Its Mechanism of Action and Clinical Efficacy and Safety | Amgen Inc. | $15,067 | 1 |
| 1st line mCRC Pmab versus Avastin containing chemotherapy | Amgen Inc. | $2,078 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 803 | 20,201 | $1.4M | $81,653 |
| 2022 | 20 | 736 | 9,237 | $946,509 | $108,556 |
| 2021 | 16 | 476 | 1,321 | $652,060 | $89,074 |
| 2020 | 1 | 16 | 18 | $10,260 | $794.17 |
Total Patients
2,031
Total Services
30,777
Medicare Billing
$280,077
Procedure Codes
63
All Medicare Procedures & Services
63 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 87 | 182 | $156,156 | $20,237 | 13.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 91 | 232 | $117,856 | $17,534 | 14.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 38 | 134 | $141,932 | $15,955 | 11.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 44 | 44 | $59,840 | $8,278 | 13.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 17 | $16,320 | $2,527 | 15.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 95 | 239 | $16,013 | $2,463 | 15.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 20 | 93 | $44,175 | $2,417 | 5.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 106 | 259 | $15,022 | $1,963 | 13.1% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 32 | 99 | $14,355 | $1,839 | 12.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 13 | 27 | $16,740 | $1,514 | 9.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 24 | 96 | $23,520 | $1,288 | 5.5% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 16 | 41 | $22,550 | $1,018 | 4.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 20 | 21 | $7,434 | $963.49 | 13.0% |
| J9263 | Injection, oxaliplatin, 0.5 mg | Office | 2023 | 12 | 11,700 | $595,900 | $658.16 | 0.1% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 12 | 5,700 | $57,000 | $656.22 | 1.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 13 | 54 | $6,696 | $650.76 | 9.7% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 13 | 18 | $5,482 | $548.64 | 10.0% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 17 | 440 | $41,800 | $344.66 | 0.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 15 | 30 | $750.00 | $252.00 | 33.6% |
| 96361 | Infusion into a vein for hydration, each additional hour | Office | 2023 | 11 | 19 | $4,275 | $223.65 | 5.2% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 40 | 184 | $1,840 | $93.41 | 5.1% |
| 83615 | Lactate dehydrogenase (enzyme) level | Office | 2023 | 11 | 15 | $675.00 | $88.80 | 13.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 21 | 488 | $2,440 | $45.76 | 1.9% |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | Office | 2023 | 13 | 33 | $495.00 | $43.69 | 8.8% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 12 | 16 | $400.00 | $32.43 | 8.1% |
About Dr. Joel Hecht, MD
Dr. Joel Hecht, MD is a Gastroenterology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790703742.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joel Hecht, MD has received a total of $106,589 in payments from pharmaceutical and medical device companies, with $1,388 received in 2024. These payments were reported across 122 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($68,768).
As a Medicare-enrolled provider, Hecht has provided services to 2,031 Medicare beneficiaries, totaling 30,777 services with total Medicare billing of $280,077. Data is available for 4 years (2020–2023), covering 63 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Hematology & Oncology
- Location Los Angeles, CA
- Active Since 07/18/2006
- Last Updated 03/25/2010
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1790703742
Products in Payments
- IMLYGIC (Biological) $15,568
- KEYTRUDA (Biological) $6,860
- Developmental Compound $6,211
- Avastin (Biological) $4,047
- OPDIVO (Biological) $3,121
- ONIVYDE (Drug) $2,318
- LONSURF (Drug) $2,172
- POC CoaguChek Meters, Strips and Accessories (Device) $2,152
- Vectibix (Biological) $2,078
- Khapzory (Drug) $1,500
- RDI Research (Device) $1,180
- Somatuline Depot (Drug) $870.00
- IMFINZI (Drug) $660.55
- Korlym (Drug) $600.00
- IMFINZI (Biological) $134.70
- KRAZATI (Drug) $78.76
- INFLECTRA (Biological) $12.40
- BRAFTOVI (Drug) $2.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Los Angeles
Bennett Roth, Md, MD
Gastroenterology — Payments: $4.3M
Gastroenterology $4.3M
Dr. Gil Melmed, M.d, M.D
Gastroenterology — Payments: $431,764
Gastroenterology $431,764
Dr. Mark Pimentel, M.d, M.D
Gastroenterology — Payments: $368,269
Gastroenterology $368,269
Dr. Venkataraman Muthusamy, Md, MD
Gastroenterology — Payments: $344,206
Gastroenterology $344,206
Dr. Joseph Pisegna, Md, MD
Gastroenterology — Payments: $257,321
Gastroenterology $257,321
Brennan Spiegel, Md, MD
Gastroenterology — Payments: $235,801
Gastroenterology $235,801